Skip to main content

FY23 Result

All figures in US$m. Key financial results were largely ahead of guidance released in May 2023 and our previous forecasts. Revenue $40.5m (10% decrease YoY, FY22 $45.0m), EBITDA $5.3m and NPAT $3.6m. Significant decrease in contribution margin to 52.5% (FY22 59.3%) and profitability with EBITDA margin of 13.1% (FY22 28.9%) and EBIT margin of 6.7% (FY22 23.8%). FY23 performance has been impacted by clinical trial patient enrolment delays, higher staffing costs prior to the restructure in May 2023 and decrease in high margin licensing mix (historically ~ 17%-19%). Clinical Trials sales contracts of $34.0m executed during FY23 were below recent years performance (FY20 $46.0m, FY21 $47.3m, FY22 $82.5m). Future contracted backlog decreased from $139.1m at the end of FY22 to $132.6m at the end of FY23. Net cash balance of $27.8m as at 30 June 2023.

Alzheimer’s Disease momentum

The company has indicated that momentum is starting to build following the significant developments with the first FDA traditional approval announced in July 2023 (lecanemab) with donanemab expected to follow later this year. The Cogstate customer base is already expanding with 3 new large pharma customers in FY24 and additional clinical trial engagement expected from the current network. Clinical trial enrolment delays experienced during FY23 have been resolved and these revenues are now expected to be recognised over FY24/25. Launch of Cognigram within the US market is targeted by late CY23 or early CY24 to support the commercialisation of new therapies (lecanemab/donanemab).

Investment View: Hold, Price Target $1.60

We maintain our Hold recommendation with price target of $1.60. Whilst we recognise that Cogstate is well positioned to capitalise on momentum in the Alzheimer’s Disease sector, we have downgraded revenue/earnings across FY24/25/26. This takes into account further potential patient enrolment delays and macroeconomic headwinds with respect to the availability of capital for R&D amongst biotech companies.

To read the full report click the button below.

View Detailed Report
Authored by Anubhav Saxena – Analyst – at Bell Potter Securities, 23 August 2023
Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client’s financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. This is general investment advice only and does not constitute advice to any person.
Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.